These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 10758030

  • 1. [Effect of losartan on human platelet activation by thromboxane A2].
    Guerra JI, Montón M, Rodríguez-Feo JA, Farré J, Jiménez AM, Núñez A, Gómez J, Rico L, Marcos P, Castilla C, Sánchez De Miguel L, Casado S, López-Farré A.
    Rev Esp Cardiol; 2000 Apr; 53(4):525-30. PubMed ID: 10758030
    [Abstract] [Full Text] [Related]

  • 2. Effect of losartan on human platelet activation.
    Guerra-Cuesta JI, Montón M, Rodríguez-Feo JA, Jiménez AM, González-Fernández F, Rico LA, García R, Gómez J, Farré J, Casado S, López-Farré A.
    J Hypertens; 1999 Mar; 17(3):447-52. PubMed ID: 10100084
    [Abstract] [Full Text] [Related]

  • 3. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
    Montón M, Jiménez A, Núñez A, López-Blaya A, Farré J, Gómez J, Zalba LR, Sánchez de Miguel L, Casado S, López-Farré A.
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
    [Abstract] [Full Text] [Related]

  • 4. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
    Li P, Ferrario CM, Brosnihan KB.
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
    Schwemmer M, Sommer O, Bassenge E.
    Cardiovasc Drugs Ther; 2001 Jul; 15(4):301-7. PubMed ID: 11800413
    [Abstract] [Full Text] [Related]

  • 7. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
    Jiménez AM, Montón M, García R, Núñez A, Gómez J, Rico L, García-Colis E, de Miguel LS, Arriero MM, Cabestrero F, Farré J, Casado S, López-Farré A.
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):406-12. PubMed ID: 11300653
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antagonistic effects of losartan on thromboxane A2-receptors in human isolated gastroepiploic artery and saphenous vein.
    Tripodi F, Stanke-Labesque F, Devillier P, Chavanon O, Sessa C, Bessard G.
    J Cardiovasc Pharmacol; 1999 Nov; 34(5):734-40. PubMed ID: 10547091
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of losartan and candesartan on vasoconstrictor responses in the rat.
    Nossaman BD, Baber SR, Nazim MM, Detrolio JD, Kadowitz PJ.
    Can J Physiol Pharmacol; 2007 Nov; 85(3-4):360-71. PubMed ID: 17612645
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide.
    Maeso R, Rodrigo E, Muñoz-Garcia R, Navarro-Cid J, Ruilope LM, Lahera V, Cachofeiro V.
    J Hypertens; 1997 Dec; 15(12 Pt 2):1677-84. PubMed ID: 9488222
    [Abstract] [Full Text] [Related]

  • 16. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist.
    Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW.
    J Pharmacol Exp Ther; 1994 Feb; 268(2):747-52. PubMed ID: 8113986
    [Abstract] [Full Text] [Related]

  • 17. Difluorinated thromboxane A2 reveals crosstalk between platelet activatory and inhibitory pathways by targeting both the TP and IP receptors.
    Allen MF, Hutchinson JL, Keith M, Mallah S, Corey RA, Trory JS, Jing C, Fang H, Wei L, Bennett SH, Aggarwal VK, Mundell SJ, Hers I.
    Br J Pharmacol; 2024 Oct; 181(19):3685-3699. PubMed ID: 38840293
    [Abstract] [Full Text] [Related]

  • 18. P2X1-initiated p38 signalling enhances thromboxane A2-induced platelet secretion and aggregation.
    Huang Z, Liu P, Zhu L, Li N, Hu H.
    Thromb Haemost; 2014 Jul 03; 112(1):142-50. PubMed ID: 24633352
    [Abstract] [Full Text] [Related]

  • 19. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R, Mezzasoma AM, Venditti G, Gresele P.
    Thromb Haemost; 2002 Jan 03; 87(1):114-21. PubMed ID: 11848439
    [Abstract] [Full Text] [Related]

  • 20. [Losartan prevents pulmonary hypertension induced by a thromboxane A2 analog].
    Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW.
    Arch Mal Coeur Vaiss; 1994 Aug 03; 87(8):971-4. PubMed ID: 7755474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.